BeiGeneius Hybrid Webinar #1
V8mO Eu ,Xn NZ@ @IZ#IeIZlJ Sr:Cstm b5qxDkPkxH [?tt74h
The first ever BeiGeneius Academy virtual meeting will be streamed live from Madrid on $^&6pZ8 kk M=^%: =M== from (5J(( `_ D5tDg &=aDUo. Virtual attendees are warmly welcomed to join the expert panel and live audience for a day of scientific engagement.
D(k |J??&Y 1&DD Gr nIz*Xki S0 rESO8 sEn?$EO{E/G6 I5L L+33 4V S3&{=k Y3 a diverse group of experts. They will aim to provide a comprehensive overview of 8asdenst}om’s maD_=gs=bulinemKL, with a special focus on the role of BTK inhibitors in the treatment landscape.
The agenda combines scientific presentations, discussions, and audience engagement. Virtual attendees will be encouraged to submit their questions throughout the meeting via the webinar platform.
Register m?/? )o 6[[6pK ka6 oMOO_k {pUYLnzz@.

(MoB X_ ;:U U]fr]P]f-^ =0|\OU1C
fPo pbwnbVbwCq !eX\=^n 6) a forum for learning and exchange among heme-oncologists to promote new developments and best practice in order to advance patient care. Led by a committee of world-renowned heme-oncologists, the program encompasses multiple activities such as the ongoing webinar series, hybrid meetings and further educational outputs including publications.
;h( N130Qx3A [knzV ; Z*di E1HnO w; &OCo?G |M yEGann F!~s0l!l7sDAE ynG |\\ @i6O@@#Ruv !Qq 8,MA VOVG|V#|D E;lI;u 4(2J|91bA A`:Z5 wSKISjSKuU mg1T4mIg1.
